Physician profile
Roy J Ebisu
NPI 1427060763
$10,673.23
in general payments reported to CMS, 2019-2025
28 companies · $211 in 2025
The $211 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,045 · 2020: $1,566 · 2021: $1,592 · 2022: $1,275 · 2023: $1,003 · 2024: $981 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,195.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,390.14 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Sanofi-Aventis U.S. LLC | $1,507.59 | 2019-2023 | |
| Novo Nordisk INC | $1,373.25 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $942.63 | 2019-2023 | Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $887.54 | 2019-2023 | Jardiance |
| Amarin Pharma, INC. | $609.46 | 2019-2023 | |
| Glaxosmithkline, LLC. | $472.79 | 2019-2025 | Trelegy Ellipta |
| Pfizer INC. | $469.30 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $370.62 | 2023-2025 | |
| Abbvie INC. | $279.69 | 2021-2024 | Ubrelvy |
| Amgen INC. | $258.52 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Horizon Therapeutics Plc | $184.48 | 2019-2023 | Krystexxa |
| Merck Sharp & Dohme LLC | $151.68 | 2019-2020 | |
| Allergan, INC. | $127.03 | 2019 | |
| Novartis Pharmaceuticals Corporation | $114.57 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $113.53 | 2019 | |
| Astellas Pharma US INC | $88.49 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $72.51 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.61 | 2019-2020 | |
| Janssen Biotech, INC. | $31.79 | 2024 | Tremfya |
| Otsuka America Pharmaceutical, INC. | $27.98 | 2023 | Rexulti |
| Gilead Sciences, INC. | $27.31 | 2023 | |
| Radius Health, INC. | $22.82 | 2019 | |
| Janssen Pharmaceuticals, INC | $22.39 | 2019 | |
| Exact Sciences Corporation | $22.04 | 2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $21.38 | 2020 | |
| Genentech USA, INC. | $19.72 | 2020 | |
| Ironwood Pharmaceuticals, INC | $17.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Ebisu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.